Clinical Trials
111 trialsLymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma
M.D. Anderson Cancer Center
FATLAS
Universitaire Ziekenhuizen KU Leuven
Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer
National Cancer Institute (NCI)
Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast Cancer
M.D. Anderson Cancer Center
Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer
M.D. Anderson Cancer Center
Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer
City of Hope Medical Center
Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer
Canadian Cancer Trials Group
Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer
Brigham and Women's Hospital
STEPS-BC
Wake Forest University Health Sciences
Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer
City of Hope Medical Center
Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer
M.D. Anderson Cancer Center
Onvansertib + Paclitaxel In TNBC
Dana-Farber Cancer Institute
ProHer
Hoffmann-La Roche
Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer
Dana-Farber Cancer Institute
Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy
M.D. Anderson Cancer Center
Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy
M.D. Anderson Cancer Center
Refining Local-Regional Therapy for IBC
Dana-Farber Cancer Institute
Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer
M.D. Anderson Cancer Center
A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer
Dana-Farber Cancer Institute
Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer
City of Hope Medical Center
TRUDI
Dana-Farber Cancer Institute
PELICAN
Institut Paoli-Calmettes
Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer
M.D. Anderson Cancer Center
Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer
City of Hope Medical Center
Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer
Thomas Jefferson University
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
Carisma Therapeutics Inc
Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer
M.D. Anderson Cancer Center
Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy
M.D. Anderson Cancer Center
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
The University of Tennessee, Knoxville
ConSIBreC
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
SHPD002
RenJi Hospital
Accelerated Radiation Therapy After Surgery in Treating Patients With Breast Cancer
Rutgers, The State University of New Jersey
Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer
M.D. Anderson Cancer Center
Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be Removed by Surgery
M.D. Anderson Cancer Center
Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer
Academic and Community Cancer Research United
SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative Inflammatory Breast Cancer
Northwestern University
Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer
SCRI Development Innovations, LLC
Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC
BerGenBio ASA
Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer
NSABP Foundation Inc
Olaparib and Radiotherapy in Inoperable Breast Cancer
The Netherlands Cancer Institute
Laser Optoacoustic and Ultrasonic Imaging System Assembly in Finding Changes in Tumors in Patients With Breast Cancer
M.D. Anderson Cancer Center
PEGASE07
UNICANCER
Capecitabine and Paclitaxel (Albumin-Stabilized Nanoparticle Formulation) in Treating Women Undergoing Surgery for Stage II or Stage III Breast Cancer
Medstar Health Research Institute
GeparX
GBG Forschungs GmbH
GeparSepto
GBG Forschungs GmbH
Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer
Northwestern University
Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy
RenJi Hospital
Pilot Study of Zirconium-89 Bevacizumab Positron Emission Tomography for Imaging Angiogenesis in Patients With Inflammatory Breast Carcinoma Receiving Preoperative Chemotherapy
Dana-Farber Cancer Institute
Beverly1
UNICANCER
Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer
University of Washington